SCHEMBL257330

SCHEMBL257330

Cc1cc2nc(Cl)cc(-c3cccc(Cl)c3)n2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 2/20 0.51
DYRK1A Q13627 2/20 0.51
DYRK2 Q92630 2/20 0.51
DYRK1B Q9Y463 2/20 0.51
CCNT1 O60563 1/20 0.51
CCNA2 P20248 1/20 0.51
CDK2 P24941 1/20 0.51
CDK9 P50750 1/20 0.51
CDK5 Q00535 1/20 0.51
CDK5R1 Q15078 1/20 0.51
NPC1 O15118 4/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 2/20 0.44
EGLN2 Q96KS0 1/20 0.43
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
IDO1 P14902 1/20 0.42
TP53 P04637 1/20 0.41
JAK2 O60674 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257329 0.89 KDM4E (0.49) DYRK3DYRK1ADYRK2DYRK1BCCNT1
SCHEMBL15020938 0.84 TP53 (0.53) NPC1RAB9ASMN1; SMN2MAPTMAPK1
SCHEMBL10072287 0.82 TP53 (0.46) NPC1RAB9ASMN1; SMN2MAPTMAPK1
SCHEMBL257316 0.78 POLB (0.61) NPC1RAB9ASMN1; SMN2MAPTMAPK1
SCHEMBL10072101 0.77 POLB (0.44) NPC1MAPTMAPK1TP53MEN1
SCHEMBL15020811 0.74 TP53 (0.43) DYRK3DYRK1ADYRK2DYRK1BCCNT1
SCHEMBL462684 0.74 MAPT (0.79) NPC1RAB9ASMN1; SMN2MAPTMAPK1
SCHEMBL256922 0.72 TP53 (0.65) NPC1RAB9AMAPTMAPK1TP53
SCHEMBL1934522 0.71 PDE10A (0.48) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL14211725 0.71 NPC1 (0.47) NPC1RAB9ASMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 DYRK3 1333/4885DYRK1A 1074/4885DYRK2 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.